AbbVie Showcases Groundbreaking Research Advancing Dermatological Care at 2026 AAD Annual Meeting AbbVie presents new clinical data related to immune-mediated skin diseases at the 2026 AAD meeting, showcasing improvements in patient outcomes.

AbbVie Showcases Groundbreaking Research Advancing Dermatological Care at 2026 AAD Annual Meeting #AbbVie #Upadacitinib #Risankizumab

AbbVie Receives Designation for Upadacitinib as Rare Disease Treatment for Takayasu Arteritis AbbVie has secured rare disease designation for Upadacitinib targeting Takayasu arteritis, a condition with limited treatment options for patients in Japan.

AbbVie Receives Designation for Upadacitinib as Rare Disease Treatment for Takayasu Arteritis #Japan #Tokyo #AbbVie #Upadacitinib #Takayasu_Arteritis

IBD Pro: IBD Pharmacist Virtual Symposium

#PediatricIBD is evolving fast. Join expert pharmacists at the 2026 #IBD #Pharmacist Virtual Symposium for real-world insights, including #upadacitinib implementation in academic pediatric centers.
Register now: https://bit.ly/4kYXE2C

AbbVie Seeks Approval for Upadacitinib as Treatment for Vitiligo in Japan AbbVie applied for approval of Upadacitinib as a treatment for vitiligo in Japan, highlighting its chronic autoimmune nature and need for new therapies.

AbbVie Seeks Approval for Upadacitinib as Treatment for Vitiligo in Japan #Japan #Tokyo #AbbVie #Upadacitinib #Vitiligo

From infection to infarction: cytomegalovirus retinitis complicated by retinal ischemia and vitreous hemorrhage in the setting of JAK inhibition - a case report An 81-year-old receiving upadacitinib for rheumatoid arthritis developed CMV retinitis complicated by delayed retinal ischemia and vitreous hemorrhage. Clinicians should be vigilant for atypical…

#MedCase - An 81-year-old receiving #upadacitinib for RA developed CMV #retinitis complicated by delayed retinal ischemia and vitreous hemorrhage.

Clinicians should be vigilant for atypical ocular complications from JAK inhibitors.

👉 buff.ly/lrgZrQr

#EyeSky #IDSky #arthritis

AbbVie Seeks Additional Approval for Upadacitinib to Treat Severe Alopecia Areata in Japan AbbVie has applied for additional approval in Japan for upadacitinib, targeting severe alopecia areata cases. This is a critical development for treatment options.

AbbVie Seeks Additional Approval for Upadacitinib to Treat Severe Alopecia Areata in Japan #Japan #Tokyo #AbbVie #Alopecia_Areata #Upadacitinib

AbbVie Reports Positive Phase 3 Results for Upadacitinib in Treating Non-Segmental Vitiligo AbbVie has announced successful Phase 3 trial results for Upadacitinib in treating Non-Segmental Vitiligo in adults and adolescents, marking a significant milestone.

AbbVie Reports Positive Phase 3 Results for Upadacitinib in Treating Non-Segmental Vitiligo #United_States #AbbVie #North_Chicago #Upadacitinib #Non-Segmental_Vitiligo

New Data Show Upadacitinib's Superiority Over Adalimumab for RA Treatment Recent findings indicate that Upadacitinib outperforms Adalimumab in patients with insufficient response to TNF inhibitors, showing promise in RA treatment.

New Data Show Upadacitinib's Superiority Over Adalimumab for RA Treatment #United_States #North_Chicago #RA_Treatment #Upadacitinib #Adalimumab

Exciting new preprint out: “A STAT5B-driven mouse model of hepatosplenic γδ T-cell lymphoma reveals therapeutic efficacy of JAK inhibition”
#STAT5B #HSTCL #upadacitinib @biorxiv-cancer.bsky.social

www.biorxiv.org/content/10.1...

Upadacitinib achieves 50% reduction in Total Vitiligo Area Scoring Index at 48 weeks A pair of phase 3 trials showed that AbbVie's daily upadacitinib 15 mg led to a 50% reduction in T-VASI 50 and a 75% reduction in F-VASI 75 at 48 weeks among adolescents 12 years and older.

According to new phase 3 data, #upadacitinib met co-primary endpoints in both Phase 3 trials for non-segmental #vitiligo at week 48, among adults and adolescents. #medsky #pedsky

Full details: www.contemporarypediatrics.com/view/upadaci...

AbbVie Reports Encouraging Results for Upadacitinib in Vitiligo Treatment Trials Recent Phase 3 studies show that AbbVie's upadacitinib significantly reduces vitiligo symptoms in adults and adolescents, marking a breakthrough in treatment options.

AbbVie Reports Encouraging Results for Upadacitinib in Vitiligo Treatment Trials #USA #North_Chicago #RINVOQ #Upadacitinib #Vitiligo

Upadacitinib for UC Helps Patients Achieve Long-Term Treatment Goals Upadacitinib is efficacious for achieving and sustaining endoscopic remission, symptom resolution, and normalization of QOL in long-term UC management.

#Upadacitinib is efficacious for helping patients with UC achieve long-term treatment goals.

Read More: https://bit.ly/4h2PpAz

Neue Indikation: Upadacitinib (RINVOQ) bei Riesenzellarteriitis Upadacitinib – eine weitere Option für die glukokortikoidsparende Therapie der Riesenzellarteriitis. Für wen kommt sie in Betracht?

Neue Indikation: #Upadacitinib (RINVOQ) bei #Riesenzellarteriitis

Upadacitinib – eine weitere Option für die glukokortikoidsparende Therapie der Riesenzellarteriitis. Für wen kommt sie in Betracht?
www.arznei-telegramm.de/html/2025_10...

Upadacitinib Shows Promising Results in Second Phase III Trial for Alopecia Areata AbbVie announces successful topline results from the second pivotal Phase III UP-AA trial evaluating Upadacitinib for patients with alopecia areata.

Upadacitinib Shows Promising Results in Second Phase III Trial for Alopecia Areata #USA #AbbVie #North_Chicago #Alopecia_Areata #Upadacitinib

AbbVie Seeks Additional Approval for Upadacitinib for Active Polyarticular Juvenile Idiopathic Arthritis AbbVie has applied for additional approval in Japan for Upadacitinib as a treatment for active polyarticular juvenile idiopathic arthritis, addressing unmet needs.

AbbVie Seeks Additional Approval for Upadacitinib for Active Polyarticular Juvenile Idiopathic Arthritis #Japan #AbbVie #Minato-ku #Upadacitinib #Polyarticular_JIA

AbbVie Announces Positive Results from Phase III Study of Upadacitinib for Alopecia Areata AbbVie has released promising results from the Phase III UP-AA trial of Upadacitinib, targeting alopecia areata patients. The findings are encouraging for those affected by this severe condition.

AbbVie Announces Positive Results from Phase III Study of Upadacitinib for Alopecia Areata #USA #AbbVie #North_Chicago #Alopecia_Areata #Upadacitinib

AbbVie Celebrates Positive Outcomes from Second Phase 3 Study of Upadacitinib for Alopecia Areata AbbVie announces encouraging results from the Phase 3 trial of upadacitinib (RINVOQ®) for alopecia areata, showing significant hair regrowth at 24 weeks.

AbbVie Celebrates Positive Outcomes from Second Phase 3 Study of Upadacitinib for Alopecia Areata #United_States #North_Chicago #Alopecia_Areata #RINVOQ #Upadacitinib

Upadacitinib: A (r)evolution in the management of GCA?

Further discussions on the role #upadacitinib will likely play in the therapeutic landscape of #giantcellarteritis treatment.
#medsky #rheumsky

🔗www.sciencedirect.com/science/article/abs/pii/...

Rinvoq Approval: A New Hope for Giant Cell Arteritis Patients AbbVie announces FDA approval for Rinvoq as a groundbreaking treatment for adult patients with Giant Cell Arteritis, marking a significant advancement in care.

Rinvoq Approval: A New Hope for Giant Cell Arteritis Patients #USA #North_Chicago #RINVOQ #Upadacitinib #GCA

Long COVID Web: April 2025 Webinar #MECFS #LongCovid #Upadacitinib #Pirfenidone

youtu.be/O0gkidDSxaw?...

AbbVie’s Rinvoq receives EC approval to treat adults with giant cell arteritis - PMLiVE The drug is now the first oral JAK inhibitor to be approved in the EU for this patient population

#AbbVie #Rinvoq #upadacitinib #giantcellarteritis #oralJAKinhibitor #JAKinhibitor #marketingauthorisation #Januskinaseinhibitor #SELECTGCAtrial #immunology #pharma #pharmaceuticals
zurl.co/ovP8I

A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis | NEJM Giant-cell arteritis is a systemic vasculitis with limited treatment options. The efficacy and safety of upadacitinib — a selective Janus kinase (JAK) inhibitor that blocks the signaling of several...

A Phase 3 Trial of #Upadacitinib for Giant-Cell Arteritis | NEJM
www.nejm.org/doi/full/10....

“In patients with giant-cell #arteritis, upadacitinib at a dose of 15 mg — but not 7.5 mg — with a 26-week glucocorticoid taper showed efficacy superior to that of placebo.”
#Rheumsky #GCA

In this week’s Evidence Based Hair podcast, I discuss the use of the JAK1 inhibitor Upadacitinib for treating dissecting cellulitis. youtu.be/y3irnGoY3BA?... #upadacitinib #scarringalopecia

Ik kan gewoon weer een vuist maken, altijd handig 😎, en muggen prikken me niet meer #upadacitinib. #reuma

Vanaf juli slik ik #upadacitinib voor reuma artritis na 5 jaar alternatief circuit doorlopen te hebben. Ik voel me herboren. Lijf nu wel een gifbelt

The first account was of #filgotinib, and this is of #upadacitinib. Both are Janus tyrosine kinase type 1 (JAK1) inhibitors.

Great to see a head to head trial in #atopicdermatitis comparing #upadacitinib to #dupilumab showing superiority for the JAKi approach - reassuring safely profile suggests a healthy population in this trial.

#EADVCongress